Indivior PLC (NASDAQ:INDV - Get Free Report) shares gapped up prior to trading on Tuesday . The stock had previously closed at $9.83, but opened at $10.40. Indivior shares last traded at $10.52, with a volume of 57,788 shares.
Analyst Ratings Changes
INDV has been the subject of a number of research reports. Piper Sandler reiterated an "overweight" rating and issued a $16.00 price objective (up previously from $15.00) on shares of Indivior in a report on Friday, October 25th. RODMAN&RENSHAW upgraded Indivior to a "strong-buy" rating in a report on Tuesday, January 28th. Finally, Rodman & Renshaw started coverage on Indivior in a report on Tuesday, January 28th. They issued a "buy" rating and a $16.00 price objective for the company.
Check Out Our Latest Report on INDV
Indivior Stock Down 5.8 %
The firm has a fifty day moving average price of $11.51 and a two-hundred day moving average price of $10.87. The stock has a market capitalization of $1.17 billion, a P/E ratio of -211.57 and a beta of 0.73.
Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported $0.32 earnings per share for the quarter, meeting the consensus estimate of $0.32. Indivior had a negative return on equity of 351.08% and a negative net margin of 0.17%. The firm had revenue of $298.00 million during the quarter, compared to the consensus estimate of $262.35 million. Sell-side analysts anticipate that Indivior PLC will post 1.55 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Indivior
Several institutional investors and hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. purchased a new stake in shares of Indivior during the fourth quarter valued at $36,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in Indivior in the fourth quarter worth about $56,000. Lazard Asset Management LLC purchased a new position in Indivior in the fourth quarter worth about $57,000. Stifel Financial Corp purchased a new position in Indivior in the third quarter worth about $100,000. Finally, Melqart Asset Management UK Ltd purchased a new position in Indivior in the third quarter worth about $132,000. 60.33% of the stock is currently owned by institutional investors.
About Indivior
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
See Also
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
